1月8日，沪深两市涨跌互现，国防军工、传媒、通用航空、芯片板块涨幅靠前。截至13点30分，医疗产 业ETF(159877.SZ)涨1.99%，乐普医疗涨6.58%。 中邮证券指出，随着病理类医疗服务价格精细化政策落地，病理医疗服务正式迈入标准化、规范化与数 字化协同发展的新阶段。政策明确肯定数字化技术的应用价值，为数字切片、远程诊断、智能分析等新 型服务模式提供支撑，加速病理学科全流程数字化转型；同时，精细化定价机制将激励医疗机构加大在 标准化建设和技术创新方面的投入，利好病理诊断及数字化病理相关企业。此外，2026年国家继续推进 医疗设备更新政策，将医疗领域纳入重点支持范围，通过优化申报条件、降低投资门槛、加大对中小企 业的扶持力度，有望推动医疗设备招投标持续景气。伴随企业渠道库存逐步出清，行业业绩拐点临近， 高端医疗设备需求尤为强劲。在此双重政策红利驱动下，医疗产业ETF有望充分受益于病理服务数字化 升级与医疗设备更新带来的需求释放，建议重点关注布局病理诊断、高端医疗设备等赛道的医疗产业 ETF(159877.SZ)。 风险提示：基金有风险，投资需谨慎。 资讯所属栏目还有更多独家策划、专家专栏，免费查阅> ...

医疗ETF（159828）涨超0.9%，高端器械与创新药成行业关注焦点。 信达证券指出，高端医疗器械领域受益于院内招采恢复驱动业务增长，内需驱动的消费医疗器械需求逐 步修复及进口品牌市场份额替代，同时骨科关节耗材集采降价已触底，骨科机器人市场份额提升及出海 带来新增量。创新器械设备在国债支持医疗设备更新政策推进下，加速进口替代并拓展海外市场，有望 走出2023年下半年以来的低谷，预计2025Q3企稳增长，2026年业绩进入较好增长态势。制药装备行业 国内边际修复&盈利能力持续回升，海外快速增长打开成长新空间，随着创新药投融资回暖、BD交易 频发驱动CMO复苏，逐步传导至制药装备行业，有望实现周期反转。CXO及生命科学上游产业链中， 具备全球影响力的CXO龙头企业、以国内业务为主的临床CRO龙头、资源型CXO及生命科学上游企业 均值得关注。 医疗ETF（159828）跟踪的是中证医疗指数（399989），该指数从A股市场中选取涉及医疗器械、医疗 服务、医疗信息化等领域的上市公司证券作为指数样本，以反映中国医疗主题上市公司证券的整体表 现。中证医疗指数成分股数量约为50只，具有行业集中度高、成长属性强的特点，主要 ...

报告导读： 医疗设备招投标规模延续较好增长，伴随设备更新政策持续落地，有望长周期 拉动医疗设备采购水平，推荐有望受益设备更新政策落地带动业绩复苏的医疗设备企业。 以上内容节选自国泰海通证券已发布的证券研究报告。 报告名称： 政策拉动国内市场有效复苏，医疗设备招采保持快速增长；报告日期：2025.12.10 报告作 者： 江珅（分析师），登记编号：S0880525090001 赵峻峰（分析师），登记编号：S0880519080017 余文心（分析师），登记编号：S0880525040111 重要提醒 本订阅号所载内容仅面向国泰海通证券研究服务签约客户。因本资料暂时无法设置访问限制，根据《证 券期货投资者适当性管理办法》的要求，若您并非国泰海通证券研究服务签约客户，为保证服务质量、 控制投资风险，还请取消关注，请勿订阅、接收或使用本订阅号中的任何信息。我们对由此给您造成的 不便表示诚挚歉意，非常感谢您的理解与配合！如有任何疑问，敬请按照文末联系方式与我们联系。 法律声明 投资建议：维持"增持"评级。 推荐有望受益设备更新政策落地带动业绩复苏的医疗设备企业。 医疗设备招投标规模保持增长， 25 年新一轮医疗设备更新 ...

Group 1 - The core viewpoint of the articles highlights a positive market sentiment in the medical device sector, with the medical device ETF (562600) experiencing a slight decline of 0.34% but achieving net inflows for 17 consecutive trading days [1] - Major provinces in China, including Jiangsu, Guangdong, and Hainan, are set to launch large-scale medical equipment update projects with a total budget exceeding 4.3 billion yuan by the third quarter of 2025 [1] - The demand for home medical devices is stabilizing post-pandemic, with a gradual recovery expected in retail pharmacy non-drug segments, indicating a potential for sustained growth in the future [1] Group 2 - The long-term investment logic in the medical device sector is clear, with the medical device ETF (562600) tracking the CSI All-Share Medical Device Index, which includes 100 representative listed companies in core medical fields [2] - Investors can also consider convenient options such as the 华夏中证全指医疗器械ETF发起式联接A (021250) and 华夏中证全指医疗器械ETF发起式联接C (021251) for exposure to the medical device sector [2]

Core Insights - The medical equipment bidding scale continues to grow, with a new round of equipment updates expected in 2025, which is anticipated to drive long-term procurement levels in the medical equipment industry [1][2][3] Industry Summary - The bidding scale for medical equipment has shown consistent growth, with significant year-on-year increases in October 2025: MRI up 2.9%, CT up 49.4%, DR up 54.4%, ultrasound up 59.9%, endoscopes up 11.6%, and surgical robots up 108.9%. Cumulatively, for the first ten months of 2025, MRI increased by 59.4%, CT by 81.6%, DR by 77.4%, ultrasound by 62.8%, endoscopes by 24.4%, and surgical robots by 42.7% [2] - Specific company performance in October 2025 shows that while Union Medical's MRI decreased by 5.9%, its CT increased by 74.7%. Mindray's ultrasound grew by 61.8%, and Kailing's endoscope increased by 96.6% [2] Policy Impact - The continuous implementation of equipment update policies is expected to significantly boost procurement levels. A joint notice from four ministries in 2024 aims for a 25% increase in medical equipment investment by 2027 compared to 2023, enhancing high-end equipment availability to levels seen in middle-income countries [3] - In 2025, the domestic market is expected to recover effectively due to policy support and increased procurement demand from medical institutions, with Union Medical reporting a revenue of 6.866 billion yuan in the first three quarters of 2025, reflecting a 23.7% year-on-year growth [3]

Core Viewpoint - The medical equipment bidding scale continues to grow, driven by the implementation of equipment renewal policies, which is expected to boost procurement levels over a long period. Companies benefiting from these policies are recommended for investment [1][4]. Summary by Sections Medical Equipment Bidding Scale - The bidding scale for new medical equipment has shown significant growth. In October 2025, the year-on-year growth rates for various equipment types were as follows: MR increased by 2.9%, CT by 49.4%, DR by 54.4%, ultrasound by 59.9%, endoscopes by 11.6%, and surgical robots by 108.9%. Cumulatively, from January to October 2025, MR grew by 59.4%, CT by 81.6%, DR by 77.4%, ultrasound by 62.8%, endoscopes by 24.4%, and surgical robots by 42.7% [3]. Equipment Renewal Policies - The implementation of equipment renewal policies is expected to drive procurement levels in the medical equipment sector. A notice issued by four ministries in 2024 aims for a 25% increase in medical equipment investment by 2027 compared to 2023. This policy is anticipated to enhance the configuration of high-end equipment to levels comparable to middle-income countries. In 2024, significant procurement plans have been announced across various provinces, indicating a robust demand for innovative diagnostic and therapeutic equipment [4]. Market Recovery and Company Performance - The domestic market is showing signs of recovery, supported by macroeconomic policies that favor public welfare and technological innovation. The medical equipment renewal policies are gradually being implemented, leading to increased procurement demand from medical institutions. For instance, in the first three quarters of 2025, the domestic revenue of United Imaging Healthcare reached 6.866 billion yuan, reflecting a year-on-year growth of 23.7%, indicating a recovery and structural upgrade in the medical equipment industry [4].

Investment Rating - Maintain Outperform rating with a target price of 167.24 RMB, representing a potential upside of 7% [1][11]. Core Insights - The company achieved revenue of 8.86 billion RMB and net profit attributable to shareholders of 1.12 billion RMB in the first three quarters of 2025, with a recurring net profit of 1.05 billion RMB [1][11]. - Domestic revenue grew by 23.70% year-on-year to 6.87 billion RMB, driven by ongoing medical equipment updates and supportive macroeconomic policies [12][4]. - Overseas revenue reached 1.99 billion RMB, a year-on-year increase of 41.97%, with the overseas revenue share rising to 22.50% [13][4]. - The service business saw a 28.44% year-on-year growth, contributing to improved profit quality [14][4]. Financial Summary - For 2025, the company is projected to achieve total revenue of 12.44 billion RMB, with a net profit of 1.81 billion RMB, reflecting a 43.7% increase from the previous year [2][5]. - The projected PE ratio for 2025 is 62.56, indicating a favorable valuation compared to peers [2][6]. - The company’s return on equity (ROE) is expected to improve from 6.3% in 2024 to 8.4% in 2025 [2][5]. Market Position - The company maintains a leading position in the medical imaging equipment sector, benefiting from a comprehensive product portfolio and continuous innovation [12][4]. - The domestic medical equipment industry is experiencing a recovery and structural upgrade, which is favorable for the company's growth [12][4]. - The company is expanding its global presence, particularly in North America, Europe, and Asia-Pacific, enhancing its market share in key regions [13][4].

Core Viewpoint - The company, Mindray Medical (300760), is experiencing a recovery in its business performance, particularly in the international market, despite facing challenges in the domestic market due to industry adjustments and geopolitical issues [2]. Group 1: Financial Performance - As of October 31, 2025, Mindray Medical's stock closed at 215.04 CNY, down 0.76%, with a turnover rate of 0.9%, trading volume of 108,900 lots, and a transaction value of 2.344 billion CNY [1]. - In the third quarter, the company reported a revenue of 9.091 billion CNY, marking a year-on-year growth of 1.53%, indicating a positive turnaround in revenue growth [2]. Group 2: Market Dynamics - The company noted that the domestic market is seeing a recovery in medical equipment bidding activities, with a significant narrowing of revenue decline in the third quarter [2]. - Internationally, the company achieved a 12% year-on-year growth in its international business during the third quarter, benefiting from a strong high-end customer base and improved localization capabilities [2]. Group 3: Investor Sentiment - On October 31, there was a net inflow of 262 million CNY from major funds, indicating positive sentiment and active positioning by institutional investors in Mindray Medical [3]. - Retail investors showed a net outflow of 134 million CNY, suggesting a divergence in sentiment between institutional and retail investors [3].

Core Viewpoint - Mindray Medical's net profit for H1 2025 reached 5.069 billion yuan, a year-on-year decline of 32.96%, with Q2 net profit at 2.440 billion yuan, down 44.55% [1] Group 1: Financial Performance - The domestic market is under pressure, leading to a decline in performance in the first half of the year [1] - EPS estimates for 2025, 2026, and 2027 are approximately 10.08 yuan, 11.99 yuan, and 14.25 yuan, respectively [1] - Corresponding PE valuations for these years are 24x, 20x, and 17x [1] Group 2: Market Outlook - The medical equipment bidding activities are expected to recover in H1 2025 as industry restructuring normalizes and equipment upgrade projects gradually commence [1] - A significant improvement in the domestic market is anticipated in Q3 2025 [1] Group 3: International Expansion - Mindray Medical has established localized production projects in 14 countries, with 11 already in production, primarily focusing on in vitro diagnostic products [1] - The product integration progress from DiaSys's original factory is proceeding smoothly [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a significant decline in revenue and net profit for the first half of 2025, with revenue at 167.43 billion yuan, down 18.45% year-on-year, and net profit at 50.69 billion yuan, down 32.96% year-on-year [4][5] - Domestic market revenue fell sharply due to intensified competition and a prolonged revenue recognition cycle, but a recovery is expected in the third quarter of 2025 as bidding activities improve [5] - The overseas market showed resilience with revenue of 83.32 billion yuan, up 5.39% year-on-year, driven by double-digit growth in certain regions and an increase in high-end customer penetration [6] - The in-vitro diagnostics (IVD) segment has become the company's largest business, with international IVD revenue experiencing notable growth despite a decline in domestic sales [7][8] Financial Performance Summary - For the first half of 2025, the company achieved revenue of 167.43 billion yuan and a net profit of 50.69 billion yuan, with significant declines in both metrics compared to the previous year [4] - The company expects revenue growth to recover in the coming years, projecting revenues of 385.88 billion yuan, 454.89 billion yuan, and 537.19 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 122.26 billion yuan, 145.36 billion yuan, and 172.75 billion yuan [9] - The projected earnings per share (EPS) for 2025, 2026, and 2027 are approximately 10.08 yuan, 11.99 yuan, and 14.25 yuan, with price-to-earnings (P/E) ratios of 24, 20, and 17 respectively [9][11]